Sandbox brain abscess: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 179: | Line 179: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadiazine]]: 2-4 g po q6-12h'''''<BR>''PLUS''<BR>▸'''''[[Pyrimethamine]] 25-50 mg po qd'''''<BR>''PLUS''<BR>▸ '''''[[Folinic acid]] 10–25 mg po qd''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadiazine]]: 2-4 g po q6-12h'''''<BR>''PLUS''<BR>▸'''''[[Pyrimethamine]] 25-50 mg po qd'''''<BR>''PLUS''<BR>▸ '''''[[Folinic acid]] 10–25 mg po qd''''' | ||
|- | |- | ||
| style=" | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[TMP-SMX]] 5/25 mg/kg po or IV q12h for 30 days ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[TMP-SMX]] 5/25 mg/kg po or IV q12h for 30 days ''''' |
Revision as of 18:16, 27 January 2014
brain abscess
Brain Abscess ▸ Primary source ▸ Contiguous source ▸ Post-traumatic ▸ Post-surgical ▸ metastatic or cryptogenic ▸ Immunocompromised |
|